We have now included acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) in our sum-of-the-parts valuation. As mentioned before, this has a minor impact on our base case, but it demonstrates the potentially broad application of anti-IL1RAP therapy, including in haematological cancers.